Bright Green Past Earnings Performance
Past criteria checks 0/6
Bright Green's earnings have been declining at an average annual rate of -28.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-28.1%
Earnings growth rate
-24.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -101.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Bright Green makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -9 | 5 | 0 |
| 30 Jun 24 | 0 | -10 | 6 | 0 |
| 31 Mar 24 | 0 | -11 | 7 | 0 |
| 31 Dec 23 | 0 | -13 | 8 | 0 |
| 30 Sep 23 | 0 | -10 | 8 | 0 |
| 30 Jun 23 | 0 | -13 | 12 | 0 |
| 31 Mar 23 | 0 | -30 | 28 | 0 |
| 31 Dec 22 | 0 | -28 | 27 | 0 |
| 30 Sep 22 | 0 | -27 | 26 | 0 |
| 30 Jun 22 | 0 | -21 | 21 | 0 |
| 31 Mar 22 | 0 | -3 | 2 | 0 |
| 31 Dec 21 | 0 | -2 | 2 | 0 |
| 30 Sep 21 | 0 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -3 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 2 | 0 |
| 31 Dec 20 | 0 | -3 | 2 | 0 |
Quality Earnings: BGXX is currently unprofitable.
Growing Profit Margin: BGXX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BGXX is unprofitable, and losses have increased over the past 5 years at a rate of 28.1% per year.
Accelerating Growth: Unable to compare BGXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGXX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: BGXX has a negative Return on Equity (-101.19%), as it is currently unprofitable.